{
  "catalysts": [
    {
      "ticker": "AQST",
      "current_price": 6.23,
      "market_cap": "$787M",
      "conviction_score": 9,
      "thesis": "Classic PDUFA run-up candidate with high volatility potential; approval would validate platform and drive significant rerating.",
      "catalyst_details": "PDUFA FDA Decision for Anaphylm (Epinephrine Sublingual Film) on January 31, 2026; Corporate update expected early Jan.",
      "absorption_status": "Unpriced; Stock down -0.85% recently, offering an optimal entry point before the typical 2-3 week pre-PDUFA ramp.",
      "earnings_date": "March 2026",
      "relative_volume": "1.2x vs 30d avg",
      "stop_loss_trigger": "$5.78 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "70% Approval Odds",
      "recency_proof": "Jan 5 2026 Pricing",
      "risk": "Regulatory delay or non-approval.",
      "expected_upside": "40-50% on approval (Small cap leverage) | Target: $7.13",
      "mispricing_evidence": "Market cap <$1B implies low expectations for a potential epinephrine standard-of-care shift.",
      "x_sentiment": "Growing retail interest",
      "atr_value": 0.3,
      "calculated_stop_loss": 5.78,
      "calculated_target": 7.13
    },
    {
      "ticker": "TVTX",
      "current_price": 38.11,
      "market_cap": "$3.5B",
      "conviction_score": 8,
      "thesis": "High-conviction PDUFA run-up play with imminent FDA decision and JPM Healthcare Conference tailwinds.",
      "catalyst_details": "PDUFA FDA Decision for FILSPARI (Sparsentan) in FSGS scheduled for January 13, 2026; anticipated pre-announcement/data during JPM week (early Jan).",
      "absorption_status": "Partially priced but momentum accumulating; +2.58% move on Jan 6 suggests traders are positioning for approval.",
      "earnings_date": "Early February 2026 (Estimate)",
      "relative_volume": "1.5x vs 30d avg",
      "stop_loss_trigger": "$34.71 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "85% Approval Odds",
      "recency_proof": "Jan 6 2026 Data",
      "risk": "FDA Complete Response Letter (CRL) or label restriction.",
      "expected_upside": "15-25% on clean approval | Target: $44.91",
      "mispricing_evidence": "Stock is trading below 52-week highs despite derisking events; options skew suggests bullish positioning.",
      "x_sentiment": "High buzz around JPM presentation",
      "atr_value": 2.27,
      "calculated_stop_loss": 34.71,
      "calculated_target": 44.91
    },
    {
      "ticker": "VRDN",
      "current_price": 30.2,
      "market_cap": "$3.0B",
      "conviction_score": 7,
      "thesis": "Dual catalyst setup: BLA acceptance confirms regulatory progress while Phase 3 data loom as a major repricing event.",
      "catalyst_details": "Jan 6, 2026: FDA accepted Veligrotug BLA (PDUFA June 30); Topline Phase 3 data for Elegrobart (VRDN-003) due Q1 2026 (imminent watch).",
      "absorption_status": "Unpriced; Market reaction to BLA acceptance was muted (+0.05%), ignoring the imminent Phase 3 asymmetric upside.",
      "earnings_date": "Mid-February 2026",
      "relative_volume": "Normal (1.0x)",
      "stop_loss_trigger": "$28.57 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "N/A",
      "recency_proof": "Jan 6 2026 PR",
      "risk": "Clinical trial failure for VRDN-003.",
      "expected_upside": "30%+ on positive Phase 3 data | Target: $33.45",
      "mispricing_evidence": "Valuation gap vs competitors in TED (Thyroid Eye Disease) market; muted response to regulatory de-risking.",
      "x_sentiment": "Moderate",
      "atr_value": 1.08,
      "calculated_stop_loss": 28.57,
      "calculated_target": 33.45
    }
  ]
}